NCT00496756 2023-10-26
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
University of Nebraska
Phase 2 Terminated
Clinical Trials
43 trialsNCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00622466 2020-10-19
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00880542 2020-08-10
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Terminated
NCT02624700 2020-07-14
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT00754923 2019-03-06
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT00126659 2018-11-20
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT03456401 2018-03-07
TOKIO
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT00722072 2018-02-26
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00632541 2018-02-14
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00126568 2018-01-19
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02122003 2017-11-22
SOAP
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Terminated
NCT01334710 2017-11-21
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
Emory University
Phase 2 Terminated
NCT00801801 2017-05-17
Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC
University of Alabama at Birmingham
Phase 2 Terminated
NCT01171482 2017-04-26
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
Seoul National University Hospital
Phase 2 Terminated
NCT00576056 2017-02-15
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
University of Pittsburgh
Phase 2 Terminated
NCT01480817 2016-04-29
Sorafenib VS TACE in HCC Patients With Portal Vein Invasion
Seoul National University Hospital
Phase 2 Terminated
NCT00510289 2016-04-19
Sorafenib in Myelodysplastic Syndrome
Duke University
Phase 2 Terminated
NCT00522301 2016-02-29
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01510756 2016-01-21
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
University of California, San Diego
Phase 2 Terminated
NCT00673361 2016-01-13
Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma
Duke University
Phase 2 Terminated
NCT00714948 2015-11-16
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01159327 2015-11-11
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
National Cancer Center, Korea
Phase 2 Terminated
NCT01342627 2015-10-06
SERCC
Centro di Riferimento Oncologico - Aviano
Phase 2 Terminated
NCT01100242 2015-09-17
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00525161 2015-01-26
Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
University of Kentucky
Phase 2 Terminated
NCT00726986 2014-11-19
Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00112905 2014-05-30
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00303966 2014-05-07
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00095693 2014-01-16
Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00110344 2013-10-11
Research Study for Patients With Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Terminated
NCT00557830 2013-07-18
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT00098618 2013-07-02
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00889343 2013-03-04
FOSCO
AIO-Studien-gGmbH
Phase 2 Terminated
NCT00618384 2012-06-07
SOCRATES
Heinrich-Heine University, Duesseldorf
Phase 2 Terminated
NCT00607438 2012-05-11
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
Veeda Oncology
Phase 2 Terminated
NCT00452387 2011-09-16
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Accelerated Community Oncology Research Network
Phase 2 Terminated
NCT00595985 2009-07-07
Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Fudan University
Phase 2 Terminated